Digital Biomarkers Market Report 2026

The digital biomarkers market size has grown exponentially in recent years. It will grow from $4.96 billion in 2025 to $6.26 billion in 2026 at a compound annual growth rate (CAGR) of 26.3%. The growth in the historic period can be attributed to growth in consumer wearable adoption, expansion of mobile health applications, increasing prevalence of chronic diseases, availability of advanced biosensors, rising interest in preventive healthcare.

The digital biomarkers market size is expected to see exponential growth in the next few years. It will grow to $15.77 billion in 2030 at a compound annual growth rate (CAGR) of 26%. The growth in the forecast period can be attributed to increasing investments in digital health platforms, rising demand for personalized healthcare monitoring, expansion of predictive health analytics, growing integration with electronic health records, increasing regulatory support for digital biomarkers. Major trends in the forecast period include increasing adoption of wearable health monitoring devices, rising use of continuous remote patient monitoring, growing integration of AI-based health analytics, expansion of sensor-based disease tracking, enhanced focus on real-time health data collection.

The increasing prevalence of chronic diseases is expected to drive the growth of the digital biomarkers market in the coming years. Chronic diseases are long-term health conditions that usually progress gradually and persist over extended periods, often throughout a person’s lifetime. The occurrence of chronic illnesses is rising due to age-related conditions such as osteoarthritis, Alzheimer’s disease, and heart disease, as well as factors including high intake of processed foods and reduced physical activity, which elevate the risk of developing chronic conditions. Digital biomarkers are utilized in the management of chronic diseases to track health indicators and disease progression in real time, enabling more timely and personalized interventions. For example, in April 2025, according to the Centers for Disease Control and Prevention, a US-based federal public health agency, 76.4% of US adults - representing approximately 194 million people - reported having one or more chronic conditions in 2023, with prevalence rates of 59.5% among young adults, 78.4% among midlife adults, and 93% among older adults. As a result, the rising prevalence of chronic diseases is fueling the growth of the digital biomarkers market.

Leading companies operating in the digital biomarkers market are increasingly pursuing strategic partnerships to broaden their market presence and strengthen their service portfolios. A strategic partnership generally involves a collaborative arrangement between two or more organizations that combine resources, expertise, and capabilities to achieve shared objectives. For instance, in September 2023, ProofPilot, a US-based provider of clinical trial automation solutions, entered into a strategic partnership with Eli Lilly and Company, a US-based pharmaceutical firm, to integrate Lilly’s innovative, patent-pending sensor cloud platform, Magnol.AI, into ProofPilot’s technology suite. Magnol.AI is an advanced platform developed to manage high-frequency sensor data with strong security and operational simplicity. This collaboration is intended to support the execution of high-quality digital health research and accelerate pre-competitive biomedical studies. The integration enables researchers to leverage real-time data science capabilities and extract meaningful insights from sensor data, aligning these insights with clinician- and patient-reported outcomes to advance digital health and biomarker research.

In March 2024, Indivi, a Switzerland-based MedTech company, partnered with Biogen to advance digital health technologies and develop digital biomarkers for Parkinson’s disease. Through this partnership, Indivi and Biogen aim to create and validate new digital endpoints for Parkinson’s disease, support continuous remote monitoring of neurological function, enhance the accuracy and frequency of disease progression measurement, and extend the application of digital biomarker technology to additional neurological disease areas. Biogen is a US-based global biotechnology company focused on developing therapies for serious neurological conditions and advancing digital health research in neuroscience.

Major companies operating in the digital biomarkers market are Pfizer Inc, Bayer AG, F Hoffmann-La Roche Ltd, Eli Lilly and Company, Koninklijke Philips NV (Philips), GE Healthcare, Biogen Inc, Garmin Ltd., Clario, Verily Life Sciences LLC, Altoida Inc., BioSerenity, Ōura Health Oy., Evidation Health Inc, AliveCor Inc, Empatica Inc, ActiGraph LLC, VivoSense Inc, BioSensics LLC, Koneksa Health Inc, ATCOR Medical Pty Ltd, Brainomix Limited.

North America was the largest region in the digital biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the digital biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the digital biomarkers market by increasing costs of imported sensors, wearable components, semiconductor chips, and advanced analytics hardware. Healthcare technology providers in North America and Europe are most affected due to dependence on imported electronic components, while Asia-Pacific faces higher production costs for wearable devices. These tariffs are raising device prices and slowing large-scale deployments. However, they are also encouraging domestic manufacturing of wearables, regional sensor innovation, and localized development of digital health ecosystems.

The digital biomarkers market research report is one of a series of new reports that provides digital biomarkers market statistics, including digital biomarkers industry global market size, regional shares, competitors with a digital biomarkers market share, detailed digital biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the digital biomarkers industry. This digital biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Digital biomarkers are objective and measurable physiological and behavioral data collected through digital technologies such as wearables, sensors, and mobile health applications. They are utilized to monitor and forecast health outcomes, supporting more accurate and personalized medical interventions. These biomarkers allow for continuous, real-time health tracking, which contributes to improved disease management and tailored treatment approaches.

The primary categories of digital biomarkers include wearables, mobile-based applications, sensors, and others. Wearable digital biomarkers consist of body-worn devices, such as smartwatches and fitness trackers, that capture physiological indicators including heart rate, physical activity, and sleep patterns. Clinical practices are classified into diagnostic digital biomarkers, monitoring digital biomarkers, predictive and prognostic digital biomarkers, and others, with applications across areas such as oncology, metabolic disorders, neurological conditions, and cardiovascular diseases. End users include healthcare companies, healthcare providers, payers, and others.

The digital biomarkers market consists of revenues earned by entities by providing services such as remote patient monitoring, health data analytics, disease prediction and management, and personalized medicine through the use of wearable devices, mobile health applications, and advanced sensors. The market value includes the value of related goods sold by the service provider or included within the service offering. The digital biomarkers market also includes sales of data analytics platforms, biometric sensors, smart glasses and headsets, voice and speech analysis tools, fitness trackers, and digital health platforms. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.